FDA Approves Camzyos for the Treatment of Obstructive Hypertrophic Cardiomyopathy
On April 28, the U.S. Food and Drug Administration (FDA) approved mavacampten (Camzyos), available in 2.5 milligram (mg), 5 mg, 10 mg, and 15 mg capsules, for the treatment of adults with symptomatic New York Heart Association (NYHA) class 2-3 obstructive hypertrophic cardiomyopathy (HOCM) to improve functional capacity and symptoms.“We’re very excited for our patients about this addition to the toolbox for management of obstructive HCM. It won’t be for everyone — nothing ever is — but it is a very welcome tool,” says Sara Saberi, MD, a cardiologist and assistant professor of internal medicine at the University of Michigan Health Frankel Cardiovascular Center in Ann Arbor.Dr. Saberi was a coauthor on the EXPLORER-HCM study published in The Lancet, which was used as the basis for the drug’s approval. Manufactured…